



Extended collaboration with Recordati in Spain

Meda has extended its collaboration with the Italian pharma company Recordati in the cardiovascular area. A long-term agreement has been signed for Lercadip[®] (lercanidipine) in Spain. The product is a calcium antagonist indicated for treatment of high blood pressure. Meda takes over an existing annual turnover of about 60 MSEK from a previous licensee. Under the agreement, Meda has undertaken to pay milestones equivalent to approximately one times annual sales.

In Spain, Meda already holds marketing rights to the combination product Coripren[®], lercanidipine + enalapril (a well-known ACE inhibitor). This product is intended to be launched during 2009. Marketing synergies are expected with Lercadip.

For more information, please contact:

Anders Larnholt, Vice President Investor Relations, tel. +46 709 458 878

MEDA AB (publ) is a leading international specialty pharma company. The company specialises in marketing and pharmaceutical development in late clinical stage. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda is represented by its own organisations in about 40 countries. Meda's products are sold in 120 countries worldwide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit www.meda.se.